Mode
Text Size
Log in / Sign up

Genomic and functional analyses address missing heritability in HDGC-like families lacking CDH1 and CTNNA1 variants.

Genomic and functional analyses address missing heritability in HDGC-like families lacking CDH1 and …
Photo by Google DeepMind / Unsplash
Key Takeaway
Consider that heterozygous copy number variants and regulatory impairments may explain missing heritability in HDGC-like families lacking CDH1 and CTNNA1 variants.

This cohort study examined 19 HDGC-like probands derived from whole-genome sequencing data, supplemented by data from six additional families. The research focused on HDGC-like families that lacked actionable germline variants in CDH1 and CTNNA1. The primary objective was to solve the issue of missing heritability in these families by identifying novel predisposition mechanisms. Functional analyses were performed using CRISPR-Cas9 editing, RT-PCR, immunohistochemistry, and microsatellite instability analysis in cell lines and tumours.

The combined analysis of chromatin accessibility, promoter interactions, and whole-genome sequencing identified that 47% of HDGC-like families within the cohort exhibited missing heritability that was subsequently explained. Specific mechanisms included heterozygous CDH3 20kb copy number variants and heterozygous 39bp-intergenic copy number variants, both of which triggered CDH1 mRNA and protein loss via homozygosity by CRISPR-Cas9 editing. Additionally, a heterozygous 2.7Kb germline copy number variant in MLH1 triggered the loss of MLH1 and CDH1/E-cadherin mRNA and protein.

Regulatory elements were found to significantly influence gene expression; each of two hypomorphic tissue-specific regulatory elements contributed 50% to CDH1 expression regulation. Secondary outcomes included CDH1 and E-cadherin protein reduction, MLH1 mRNA and protein reduction, mucin gene impairment, and immune-related pathway impairment. Microsatellite instability was also observed in relevant cases. No adverse events, serious adverse events, discontinuations, or tolerability issues were reported, as the study involved genomic analysis and functional editing in cell lines rather than clinical intervention.

Key limitations include the small sample size of 19 probands and six families, and the setting was not reported. The study offers no HDGC-targeted life-saving disease prevention measures for HDGC-like families lacking CDH1 and CTNNA1 actionable germline variants. While these findings elucidate molecular mechanisms, clinical application remains uncertain given the observational nature of the cohort and the lack of prospective validation in a broader population.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Missing heritability in hereditary diffuse gastric cancer (HDGC) ranges from 60 to 90%. These HDGC-like families, despite complying with HDGC clinical criteria, lack CDH1 and CTNNA1 actionable germline variants, and are not offered HDGC-targeted life-saving disease prevention measures. Herein, we explored novel HDGC predisposition mechanisms affecting the CDH1-regulatory network. We called single-nucleotide (SNV) and copy-number variants (CNV) from 19 HDGC-like probands from whole-genome sequencing data and performed gene-ontology analysis. Chromatin enhancer marks and CDH1 promoter interactions were evaluated in normal stomach by ChIP-seq, ATAC-seq and 4C-seq, variant causality was assessed by RT-PCR, immunohistochemistry and microsatellite instability (MSI) analysis in tumours. Functional analysis was performed using CRISPR-Cas9, RT-PCR and flow cytometry in cell lines, and enhancer assays using mouse embryos. Within the CDH1 topologically associating domain (TAD), we found two deletions in Family F4 and F9. F4 carried a heterozygous CDH3 20kb-CNV triggering CDH1 mRNA/protein loss in homozygosity by CRISPR-Cas9 editing, similarly to a CDH1 coding deletion. This 20kb sequence encloses two hypomorphic tissue-specific regulatory elements (REs), each contributing 50% to CDH1 expression regulation. F9 carried a heterozygous 39bp-intergenic CNV downstream of CDH1, triggering CDH1 mRNA/protein loss by CRISPR-Cas9. F15, presenting gastric but not colorectal cancer, carried an MLH1 heterozygous 2.7Kb germline CNV overlapping a stomach-specific RE found by ChIP-seq. The gastric tumour of mixed histology displayed Microsatellite instability (MSI), reduced MLH1 mRNA and protein, and reduced CDH1 and E-cadherin protein. CRISPR-Cas9 clones mimicking the MLH1 heterozygous CNV, triggered loss of MLH1 and CDH1/E-cadherin mRNA and protein, similar to a coding deletion. Beyond the CDH1 TAD and tumour risk syndrome genes, multiple deletions of stomach accessible chromatin sequences were found in particularly young-affected individuals from additional 6 families. This oligogenic pattern impaired specifically mucin genes and multiple immune-related pathways. Herein, we pinpointed novel mechanisms behind HDGC predisposition. One involves deletions of CDH1-REs in the TAD or stomach-specific CDH1-REs in the MLH1 locus. The second involves multiple deletions of stomach REs affecting mucin and immune-related genes, favouring a gastric immune-deficient phenotype. Altogether, by combining stomach-specific chromatin accessibility and promoter interactions with whole genome sequencing, we solved the missing heritability in 47% of HDGC-like families within our cohort.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.